Dexmedetomidine and acute kidney injury in patients with sepsis: a retrospective cohort study
Authors' conclusion
While there was no association between dexmedetomidine administration and AKI in our overall cohort of patients with sepsis, we observed reduced odds of developing AKI in older patients (aged > 65 yr) who received dexmedetomidine.
Study context
- Population
- Adults with sepsis73 per group matched
- Participants
- 331 adults
- Exposure
- Dexmedetomidine infusion vs no dexmedetomidine infusion
- Dexmedetomidinen = 73
- Nondexmedetomidinen = 258reference
- Outcome
- Incidence of AKI (Kidney Disease Improving Global Outcomes (KDIGO) criteria)
- Follow-up
- Within seven days
Methodological detailsmultivariable logistic regression, 1:1 propensity-score matched
- Multivariable logistic regression
- 1:1 propensity-score matched
Main finding
As reported in the abstract
AKI, entire cohort
P = 0.61
- Acute kidney injury (AKI) overall in the cohort
- 190/331 (57.4%)
Observational data: associations, not effects.
Further findings
AKI within 7 days, propensity-matched cohort
P = 0.31
RRT
P = 0.61
30-day mortality
P = 0.27
| Outcome | aOR (95% CI) | P value | |
|---|---|---|---|
| AKI, age > 65 yr (subgroup) | 0.25 (0.07–0.90) | P = 0.03 | |
| 0.050.21520Adjusted odds ratio (log scale) |
- AKI within 7 days, propensity-matched cohort: 1:1 propensity-score-matched cohort
- AKI, age > 65 yr (subgroup): statistically significant interaction between age > 65 yr and dexmedetomidine
AKI within 7 days, propensity-matched cohort
- Incidence of AKI not different between groups
RRT
- No significant difference between groups
30-day mortality
- No significant difference between groups
Original publication
Dexmedetomidine and acute kidney injury in patients with sepsis: a retrospective cohort study. Can J Anaesth. Published 9 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →